David E Piccioni
Overview
Explore the profile of David E Piccioni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sarkaria J, Ballman K, Kizilbash S, Sulman E, Giannini C, Friday B, et al.
JAMA Oncol
. 2024 Oct;
10(12):1637-1644.
PMID: 39480453
Importance: The prognosis for patients with glioblastoma is poor following standard therapy with surgical resection, radiation, temozolomide, and tumor-treating fields. Objectives: To evaluate the combination of veliparib and temozolomide in...
2.
Manning P, Srinivas S, Bolar D, Rajaratnam M, Piccioni D, McDonald C, et al.
Front Radiol
. 2024 Apr;
4:1345465.
PMID: 38562528
Purpose: Conventional contrast-enhanced MRI is currently the primary imaging technique used to evaluate radiation treatment response in meningiomas. However, newer perfusion-weighted MRI techniques, such as 3D pseudocontinuous arterial spin labeling...
3.
Bota D, Taylor T, Piccioni D, Duma C, LaRocca R, Kesari S, et al.
J Exp Clin Cancer Res
. 2022 Dec;
41(1):344.
PMID: 36517865
Background: Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2)...
4.
Liau L, Ashkan K, Brem S, Campian J, Trusheim J, Iwamoto F, et al.
JAMA Oncol
. 2022 Nov;
9(1):112-121.
PMID: 36394838
Importance: Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed. Objective: To investigate whether adding autologous tumor lysate-loaded dendritic cell...
5.
Brastianos P, Twohy E, Gerstner E, Kaufmann T, Iafrate A, Lennerz J, et al.
J Clin Oncol
. 2022 Oct;
41(3):618-628.
PMID: 36288512
Purpose: Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with loss. Given the predominance of mutations in...
6.
Fu S, Piccioni D, Liu H, Lukas R, Kesari S, Aregawi D, et al.
Sci Rep
. 2021 Nov;
11(1):22355.
PMID: 34785698
WT2725 is a Wilms' tumor gene 1 (WT1)-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1 tumors in human leukocyte antigen (HLA)-A*0201 and/or HLA-A*0206 patients. Here, we report the...
7.
Okamura R, Piccioni D, Boichard A, Lee S, Jimenez R, Sicklick J, et al.
Int J Cancer
. 2021 Jan;
148(11):2839-2847.
PMID: 33497479
Plasma cell-free DNA (cfDNA) is emerging as an important diagnostic tool in cancer. However, cfDNA alterations may differ from those in tissue and sometimes may reflect processes unrelated to the...
8.
Charo L, Eskander R, Okamura R, Patel S, Nikanjam M, Lanman R, et al.
Mol Oncol
. 2020 Sep;
15(1):67-79.
PMID: 32881280
Molecular characterization of cancers is important in dictating prognostic factors and directing therapy. Next-generation sequencing of plasma circulating tumor DNA (ctDNA) offers less invasive, more convenient collection, and a more...
9.
Manning P, Daghighi S, Rajaratnam M, Parthiban S, Bahrami N, Dale A, et al.
J Neurooncol
. 2020 Apr;
147(3):681-690.
PMID: 32239431
Purpose: To use 3D pseudocontinuous arterial spin labeling (3D PCASL) and dynamic susceptibility contrast-enhanced (DSC) perfusion MRI to differentiate progressive disease from pseudoprogression in patients with glioblastoma (GBM). Methods: Thirty-two...
10.
Daghighi S, Bahrami N, Tom W, Coley N, Seibert T, Hattangadi-Gluth J, et al.
Front Oncol
. 2020 Feb;
10:24.
PMID: 32047723
Immunotherapy is increasingly used in the treatment of glioblastoma (GBM), with immune checkpoint therapy gaining in popularity given favorable outcomes achieved for other tumors. However, immune-mediated (IM)-pseudoprogression is common, remains...